These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance. Kurtenkov O, Klaamas K. Biomed Res Int; 2017; 2017():6097647. PubMed ID: 28316982 [Abstract] [Full Text] [Related]
6. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer. Baldus SE, Zirbes TK, Glossmann J, Fromm S, Hanisch FG, Mönig SP, Schröder W, Schneider PM, Flucke U, Karsten U, Thiele J, Hölscher AH, Dienes HP. Oncology; 2001; 61(2):147-55. PubMed ID: 11528254 [Abstract] [Full Text] [Related]
8. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis. Rabassa ME, Croce MV, Pereyra A, Segal-Eiras A. BMC Cancer; 2006 Oct 25; 6():253. PubMed ID: 17064405 [Abstract] [Full Text] [Related]
11. Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential. Kurtenkov O, Izotova J, Klaamas K, Sergeyev B. Biomed Res Int; 2014 Oct 25; 2014():830847. PubMed ID: 25276822 [Abstract] [Full Text] [Related]
18. The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients. Smorodin E, Sergeyev B, Klaamas K, Chuzmarov V, Kurtenkov O. Int J Med Sci; 2013 Oct 25; 10(12):1674-82. PubMed ID: 24151439 [Abstract] [Full Text] [Related]